Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Conditions
End Stage Renal Failure on Dialysis, Complication of Hemodialysis
Interventions
Placebo, Ramipril, Valsartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Conditions
Hypertension
Interventions
Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care, Valsartan, Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Conditions
Hypertension
Interventions
valsartan plus hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
607 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
Interventions
Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure
Interventions
Sacubitril-Valsartan Tab 97-103 MG, Valsartan 160mg, Placebo Oral Tablet
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Heart Failure, Congestive
Interventions
Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate
Drug
Lead sponsor
Heart Center Research, LLC
Network
Eligibility
19 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Huntsville, Alabama
Conditions
Heart Failure, Heart Dysfunction
Interventions
Sacubitril-valsartan, Valsartan, Carvedilol
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Stage 2 Hypertension
Interventions
Valsartan/aliskiren, Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,797 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Phase 4 Interventional Results available

Effect of DPP4 Inhibition on Vasoconstriction

NCT02639637
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee